Home > Oncology > SABCS 2021 > Miscellaneous > Olaparib is well tolerated as an additional treatment

Olaparib is well tolerated as an additional treatment

Presented By
Dr Patricia Ganz, UCLA School of Medicine, CA, USA
Conference
SABCS 2021
Trial
Phase 3, OlympiA
Adjuvant treatment with the PARP-inhibitor olaparib showed beneficial effects for patients with BRCA1/2 mutations and high-risk, HER2-negative, early-stage, primary breast cancer. In addition, patient-reported outcomes (PROs) demonstrated no negative impact on the quality of life. OlympiA (NCT02032823) is a randomised, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy and safety of the PARP-inhibitor olaparib in patients with germline BRCA1/2 mutations and high-risk, HER2-negative, early-stage, primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy. A recently published interim analysis at a median follow-up of 2.5 years showed the 3-year invasive disease–free survival to be 85.9% in the olaparib group and 77.1% in the placebo g...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on